Enter your email address
Submit
Write your message
International Journal of Medical Laboratory
Shahid Sadoughi University of Medical Sciences
Sun, Mar 9, 2025
[Archive]
Ghasem Miri-Aliabad * 
, Hossein Ali Khazaei , Seyed Mohammad Nasiraldin Tabatabaei , Ali Khajeh , Zeinab Nasri Nasrabadi , Reyhaneh Rezvani Kharashadizadeh
, Hossein Ali Khazaei , Seyed Mohammad Nasiraldin Tabatabaei , Ali Khajeh , Zeinab Nasri Nasrabadi , Reyhaneh Rezvani Kharashadizadeh
Department of Pediatrics, Ali Asghar Children’s Hospital, Iran University of Medical Sciences, Tehran, Iran
Abstract: (8 Views)
Introduction: Liver involvement is observed in various malignancies and is characterized by abnormal liver function tests, imaging findings, or clinical signs linked to the liver. This study aimed to evaluate hepatic manifestations in childhood malignancies.
Materials and Methods: This cross-sectional descriptive study analyzed hepatic manifestations in children under 18 with malignancy admitted to the pediatric oncology ward between April 2016 and April 2020.
Results: Among the 130 patients studied, 82 (63%) were male, and 48 (37%) were female. The mean age was 5.9 ± 4.31 years. Patients with hepatoblastoma, lymphoma, and leukemia exhibited the highest rates of abnormal liver enzyme levels. Elevated aspartate aminotransferase levels were most frequently noted in patients with hepatoblastoma (83.3%), non-Hodgkin’s lymphoma (58.3%), and acute lymphoblastic leukemia (32.7%). Similarly, elevated alanine aminotransferase levels were highest in patients with hepatoblastoma (50%), Hodgkin’s lymphoma (16.7%), and acute myeloblastic leukemia (22.2%). Hepatomegaly was the most common liver-related clinical sign, occurring in 41.5% of patients.
Conclusion: The findings indicate that clinical and laboratory liver involvement is highly prevalent among children with malignancies. Such involvement can provide insights into disease progression and play a critical role in treatment planning.
Materials and Methods: This cross-sectional descriptive study analyzed hepatic manifestations in children under 18 with malignancy admitted to the pediatric oncology ward between April 2016 and April 2020.
Results: Among the 130 patients studied, 82 (63%) were male, and 48 (37%) were female. The mean age was 5.9 ± 4.31 years. Patients with hepatoblastoma, lymphoma, and leukemia exhibited the highest rates of abnormal liver enzyme levels. Elevated aspartate aminotransferase levels were most frequently noted in patients with hepatoblastoma (83.3%), non-Hodgkin’s lymphoma (58.3%), and acute lymphoblastic leukemia (32.7%). Similarly, elevated alanine aminotransferase levels were highest in patients with hepatoblastoma (50%), Hodgkin’s lymphoma (16.7%), and acute myeloblastic leukemia (22.2%). Hepatomegaly was the most common liver-related clinical sign, occurring in 41.5% of patients.
Conclusion: The findings indicate that clinical and laboratory liver involvement is highly prevalent among children with malignancies. Such involvement can provide insights into disease progression and play a critical role in treatment planning.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
